Latest news with #MDT
Yahoo
15 hours ago
- Business
- Yahoo
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Medtronic (MDT) was up +2.17% at $91.65. This move outpaced the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.41%, and the Nasdaq, a tech-heavy index, lost 0.39%. The stock of medical device company has risen by 4.35% in the past month, leading the Medical sector's loss of 1.83% and undershooting the S&P 500's gain of 5.88%. The upcoming earnings release of Medtronic will be of great interest to investors. The company's earnings report is expected on August 19, 2025. In that report, analysts expect Medtronic to post earnings of $1.23 per share. This would mark no growth from the year-ago period. Alongside, our most recent consensus estimate is anticipating revenue of $8.37 billion, indicating a 5.73% upward movement from the same quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $5.55 per share and a revenue of $35.29 billion, indicating changes of +1.09% and +5.22%, respectively, from the former year. It is also important to note the recent changes to analyst estimates for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. Medtronic is currently a Zacks Rank #4 (Sell). From a valuation perspective, Medtronic is currently exchanging hands at a Forward P/E ratio of 16.17. Its industry sports an average Forward P/E of 18.47, so one might conclude that Medtronic is trading at a discount comparatively. It is also worth noting that MDT currently has a PEG ratio of 2.33. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 2.22. The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 177, which puts it in the bottom 29% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
New Straits Times
a day ago
- Entertainment
- New Straits Times
#SHOWBIZ: 'The Saga of Taj Theatre' combines classical dance and comedy
KUALA LUMPUR: Mahavidya Dance Theatre (MDT) is set to return to the stage with 'The Saga of Taj Theatre', a captivating multi-genre performance. This unique production seamlessly blends Bharatanatyam, comedy theatre, and film projection into a single, compelling experience. The show will be staged at the Damansara Performing Arts Centre (DPAC) on July 26 and 27. This original production tells the story of an old theatre on the brink of demolition – a symbolic setting where the past and future dramatically collide. As the narrative unfolds, the performance beautifully incorporates a vibrant dance drama dedicated to Lord Brahma, a deity long associated with creation in Indian cultural tradition. To ensure a deeper audience connection, all dances are fully subtitled in English, and the innovative use of multimedia projections provides an accessible and visually rich storytelling experience. More than 20 performers will take to the stage in this grand production. The choreography and music are the result of a collaboration between award-winning artists from Malaysia and India, drawing from ancient South Indian classical traditions. Percussion arrangements are by Maestro Kalaimamani S. Gopakumar, with lyrics penned by Nirmala Raghavan. MDT founder Sheela Raghavan-Tan is responsible for the dance research and choreography. MDT operates as a non-profit dance school, offering free performing arts training to children from all backgrounds. Proceeds from 'The Saga of Taj Theatre' will directly support the expansion of these outreach programmes and help create more platforms for young, aspiring performers. Tickets for both the 5pm and 8pm shows are by donation.
News18
6 days ago
- Health
- News18
Designer Genes: Are '3-Parent Babies' The Answer To Hereditary Diseases?
Eight children in the UK have been spared from devastating genetic diseases thanks to a new three-person in vitro fertilisation (IVF) technique In a groundbreaking medical advancement that brings hope to families affected by severe hereditary diseases, the United Kingdom has witnessed the birth of eight children through a revolutionary method called Mitochondrial Donation Treatment (MDT). Often referred to as 'three-parent DNA", this technique offers a powerful solution to prevent the transmission of debilitating mitochondrial diseases from mother to child. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria, the cell's 'powerhouses", fail to produce sufficient energy for the body to function properly. These diseases can lead to a range of debilitating and often fatal symptoms, affecting the brain, heart, muscles, lungs, and kidneys. Since mitochondria contain their own small amount of DNA (mtDNA), inherited exclusively from the mother, women with faulty mitochondrial genes face the distressing possibility of passing these severe conditions to all their children. Maternal Spindle Transfer (MST): This method involves removing the nucleus (which contains the majority of the parents' DNA) from the mother's egg. A donor egg is then taken, and its nucleus is removed, leaving behind healthy cytoplasm containing the donor's mitochondria. The mother's nucleus is inserted into the enucleated donor egg. This reconstructed egg, now containing the mother's nuclear DNA and the donor's healthy mitochondrial DNA, is fertilised with the father's sperm. Pronuclear Transfer (PNT): Conducted after fertilisation, this technique involves fertilising both the mother's egg and a donor egg with the father's sperm, creating two embryos. The pronuclei (which contain the nuclear DNA from both parents) are removed from the fertilised mother's egg (which has faulty mitochondria). These pronuclei are then transferred into the fertilised donor egg, from which its pronuclei have been removed. The resulting embryo, containing the parents' nuclear DNA and the donor's healthy mitochondrial DNA, is implanted into the mother's womb. In both techniques, the resulting embryo inherits approximately 99.8% of its DNA from the biological mother and father and a small fraction (about 0.2%) from the mitochondrial donor. This is why it is called 'three-parent DNA"—the genetic material comes from three individuals, yet the majority of traits, appearance, and characteristics are determined by the primary parents' nuclear DNA. The mitochondrial DNA only carries instructions for the mitochondria, not for other bodily features. The UK became the first country to legalise MDT in 2015, following extensive ethical and scientific reviews. The procedure is regulated by the Human Fertilisation and Embryology Authority (HFEA), which provides strict guidelines and oversight. The first baby born using MDT in the UK was confirmed in 2016, and the recent announcement of eight children born using this method highlights the cautious and controlled application of this advanced reproductive technology. MDT offers immense hope to families facing the devastating prospect of passing on incurable diseases, such as certain forms of cancer, severe neurological disorders, heart conditions, and muscle weaknesses. It represents a significant advance in reproductive medicine, offering the chance for healthy children where previously there was none. Although still a rare procedure due to its complexity and ethical considerations, its success in the UK marks a pivotal moment in the fight against inherited genetic diseases. Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
6 days ago
- Health
- Mint
Medical breakthrough in UK! Babies born after IVF using DNA from three people
At least eight babies have been born in the UK using DNA from three people, thanks to a groundbreaking fertility technique designed to stop the passing on of inherited genetic diseases. Known as mitochondrial donation treatment (MDT), the method involves using healthy mitochondria from a donor to replace faulty ones in a mother's egg—preventing serious and often fatal conditions linked to mitochondrial defects, Sky News reported. These babies carry nuclear DNA from their biological mother and father, and a small portion of mitochondrial DNA from a female donor. Early medical follow-ups show no signs of the disorders the treatment aims to prevent, offering hope to families with a history of such illnesses. Mitochondria are tiny structures in cells that produce energy. When they don't work properly, they can lead to severe conditions affecting the brain, muscles, heart and other organs. MDT works by removing the faulty mitochondria in a woman's egg and replacing them with healthy ones from a donor. The mother's nuclear DNA, which makes up most of a person's genes, is kept intact. As a result, the baby inherits DNA from three people: the mother, the father, and the donor woman. However, the donor's contribution is less than 1% of the child's total genetic material. The UK became the first country to approve the use of mitochondrial donation in 2015. The Human Fertilisation and Embryology Authority (HFEA) regulates the treatment, and the Newcastle Fertility Centre has led the procedure under strict guidelines. Though some have raised ethical concerns about the idea of 'three-parent babies' and the limits of genetic intervention, many experts argue that the benefits of preventing devastating diseases outweigh these concerns. So far, the babies born through MDT in the UK are healthy and show no signs of mitochondrial disease. Doctors say the early results are 'highly promising', though more long-term monitoring is needed. Families involved in the programme have called the treatment 'life-saving' and expressed deep gratitude. Experts stress that MDT is not a cure for people already affected by mitochondrial conditions, but rather a way to prevent these illnesses in future generations. While the UK leads in allowing and overseeing this treatment, other countries remain cautious. In the US, such procedures are permitted only as part of clinical trials. Scientists around the world are closely watching the UK's results. Many believe that with careful regulation, MDT could become a routine option for families at risk, helping to stop certain genetic diseases before they begin.
Time of India
6 days ago
- Health
- Time of India
UK's first 3-parent IVF births: 8 healthy babies born; breakthrough in genetic medicine
AI- Representative Image Doctors in the UK have confirmed the birth of eight healthy babies conceived using DNA from three individuals through an IVF technique designed to prevent inherited mitochondrial disorders. The procedure, known as mitochondrial donation treatment (MDT), combines the DNA of the biological mother and father with healthy mitochondrial DNA from a female donor. It is designed to replace faulty mitochondria—the energy-producing structures in cells—with healthy ones from a donor, thereby stopping the transmission of potentially fatal genetic conditions. According to Sky News, this advancement "takes medicine into uncharted territory." The technique was developed to prevent inherited mitochondrial disorders, which affect around 1 in 5, 000 babies and can cause serious issues such as brain damage, muscle failure, blindness, or death. All eight babies born through this technique in the UK are reported to be healthy. The human fertilisation and embryology authority (HFEA), which regulates fertility treatments in the UK, had previously approved the use of MDT on a case-by-case basis. The Guardian quoted scientists saying, "This is not about creating designer babies. It's a way to prevent devastating illnesses." They also noted that long-term follow-up is still required to fully assess the safety and effectiveness of the method. Meanwhile, NPR highlighted that the first baby born using this approach was in Mexico in 2016. The UK is the first country to officially legalise the technique under regulatory supervision. While promising, experts remain cautious. 'There's still much to learn,' one researcher told NPR, adding that "monitoring these children over time is essential."
